Ann Dermatol.  2014 Aug;26(4):517-520. 10.5021/ad.2014.26.4.517.

Tazarotene-Induced Gene 3 May Affect Inflammatory Angiogenesis in Psoriasis by Downregulating Placental Growth Factor Expression

• Jeon SY
• Ha SM
• Ko DY
• Ku BS
• Lee CY
• Song KH
• Kim KH

• KMID: 2265597
• DOI: http://doi.org/10.5021/ad.2014.26.4.517

Abstract

No abstract available.

MeSH Terms

Psoriasis*

Figure

• 

  Fig. 1 Placental growth factor (PlGF) (A~C) and tazarotene-induced gene 3 (TIG3) (D~F) expression in psoriatic lesions. (A) PlGF was expressed in the keratinocytes and endothelial cells, and was overexpressed before tazarotene treatment. PlGF expression reduced after treatment with tazarotene at (B) 4 weeks and (C) 12 weeks7. (D~F) TIG3 expression within the epidermal keratinocytes and the dermal vascular endothelial cells (D) before treatment with tazarotene and (E) after 4 weeks of tazarotene treatment. (F) TIG3 expression increased after 12 weeks of tazarotene treatment. (A~C) PIGF stain, ×400; (D~F) TIG3 stain, ×200; dotted lines, ×400.

• 

  Fig. 2 The expression of p53 in psoriatic lesions (p53 stain, ×200; insets, ×400). (A) Dermal endothelial cells and epidermal keratinocytes within untreated psoriatic lesions did not express p53. (B) An increased expression of p53 was evident within the epidermal keratinocytes of psoriatic lesions treated with tazarotene for up to 12 weeks.

Reference

1. Creamer D, Sullivan D, Bicknell R, Barker J. Angiogenesis in psoriasis. Angiogenesis. 2002; 5:231–236.

2. Oura H, Bertoncini J, Velasco P, Brown LF, Carmeliet P, Detmar M. A critical role of placental growth factor in the induction of inflammation and edema formation. Blood. 2003; 101:560–567.

3. Detmar M, Brown LF, Claffey KP, Yeo KT, Kocher O, Jackman RW, et al. Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis. J Exp Med. 1994; 180:1141–1146.

4. Bhushan M, McLaughlin B, Weiss JB, Griffiths CE. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol. 1999; 141:1054–1060.

5. Kuroda K, Sapadin A, Shoji T, Fleischmajer R, Lebwohl M. Altered expression of angiopoietins and Tie2 endothelium receptor in psoriasis. J Invest Dermatol. 2001; 116:713–720.

6. Odorisio T, Cianfarani F, Failla CM, Zambruno G. The placenta growth factor in skin angiogenesis. J Dermatol Sci. 2006; 41:11–19.

7. Ku BS, Lee CW, Kim KH. Therapeutic effects of tazarotene on psoriasis and its potential action mechanism in inflammatory angiogenesis. Korean J Dermatol. 2007; 45:898–907.

8. Eckert RL, Sturniolo MT, Jans R, Kraft CA, Jiang H, Rorke EA. TIG3: a regulator of type I transglutaminase activity in epidermis. Amino Acids. 2009; 36:739–746.

9. Ou CC, Hsu SC, Hsieh YH, Tsou WL, Chuang TC, Liu JY, et al. Downregulation of HER2 by RIG1 involves the PI3K/Akt pathway in ovarian cancer cells. Carcinogenesis. 2008; 29:299–306.

10. Bottomley MJ, Webb NJ, Watson CJ, Holt L, Bukhari M, Denton J, et al. Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid. Clin Exp Immunol. 2000; 119:182–188.